AlphaQuest LLC Buys 3,083 Shares of Doximity, Inc. (NASDAQ:DOCS)

AlphaQuest LLC raised its stake in Doximity, Inc. (NASDAQ:DOCS) by 213.2% during the fourth quarter, HoldingsChannel.com reports. The fund owned 4,529 shares of the company’s stock after purchasing an additional 3,083 shares during the quarter. AlphaQuest LLC’s holdings in Doximity were worth $242,000 at the end of the most recent reporting period.

Other hedge funds have also bought and sold shares of the company. Global Retirement Partners LLC grew its position in shares of Doximity by 468.1% during the fourth quarter. Global Retirement Partners LLC now owns 534 shares of the company’s stock valued at $29,000 after purchasing an additional 440 shares in the last quarter. UMB Bank n.a. increased its stake in Doximity by 69.1% in the 4th quarter. UMB Bank n.a. now owns 575 shares of the company’s stock worth $31,000 after acquiring an additional 235 shares during the last quarter. Larson Financial Group LLC raised its holdings in shares of Doximity by 49.4% during the 4th quarter. Larson Financial Group LLC now owns 756 shares of the company’s stock worth $40,000 after acquiring an additional 250 shares in the last quarter. Morse Asset Management Inc bought a new position in shares of Doximity during the 3rd quarter valued at approximately $46,000. Finally, IFP Advisors Inc grew its holdings in shares of Doximity by 344.1% in the fourth quarter. IFP Advisors Inc now owns 1,328 shares of the company’s stock valued at $71,000 after purchasing an additional 1,029 shares in the last quarter. Hedge funds and other institutional investors own 87.19% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts recently issued reports on DOCS shares. Leerink Partnrs raised shares of Doximity from a “hold” rating to a “strong-buy” rating in a research note on Friday, February 7th. Wells Fargo & Company reiterated an “equal weight” rating on shares of Doximity in a research report on Friday, February 7th. The Goldman Sachs Group boosted their price objective on Doximity from $58.00 to $80.00 and gave the stock a “neutral” rating in a research note on Monday, February 10th. Mizuho lifted their target price on Doximity from $55.00 to $65.00 and gave the stock a “neutral” rating in a report on Monday, February 10th. Finally, Stephens started coverage on Doximity in a report on Friday, December 20th. They set an “equal weight” rating and a $55.00 price target on the stock. Eleven research analysts have rated the stock with a hold rating, eight have given a buy rating and two have given a strong buy rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $64.22.

Insider Buying and Selling at Doximity

In related news, Director Timothy S. Cabral sold 20,000 shares of the company’s stock in a transaction on Monday, February 3rd. The stock was sold at an average price of $57.62, for a total transaction of $1,152,400.00. Following the completion of the sale, the director now directly owns 6,360 shares in the company, valued at $366,463.20. This represents a 75.87 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link. Insiders own 37.40% of the company’s stock.

Doximity Stock Performance

Shares of DOCS opened at $63.33 on Friday. The stock has a market capitalization of $11.82 billion, a PE ratio of 63.33, a PEG ratio of 4.10 and a beta of 1.34. The company has a 50 day moving average price of $63.63 and a 200-day moving average price of $52.60. Doximity, Inc. has a fifty-two week low of $22.96 and a fifty-two week high of $85.21.

Doximity Company Profile

Doximity, Inc operates a cloud-based digital platform for medical professionals in the United States. The company's platform provides its members with tools built for medical professionals, enabling them to collaborate with their colleagues, coordinate patient care, conduct virtual patient visits, stay up to date with the latest medical news and research, and manage their careers.